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Molecular mechanisms driving transition from simple steatosis to nonalcoholic steatohepatitis (NASH), a critical step in the
progression of nonalcoholic fatty liver disease (NAFLD) to cirrhosis, are poorly defined. This study aimed at investigating the
role of the purinergic receptor 2X7 (PR2X7), through the NLRP3 inflammasome, in the development of NASH. To this end,
mice knockout for the Pr2x7 gene (Pr2x7
−/−) and coeval wild-type (WT) mice were fed a high-fat diet (HFD) or normal-fat diet
for 16 weeks. NAFLD grade and stage were lower in Pr2x7
−/− than WT mice, and only 1/7 Pr2x7
−/− animals showed evidence of
NASH, as compared with 4/7 WT mice. Molecular markers of inflammation, oxidative stress, and fibrosis were markedly
increased in WT-HFD mice, whereas no or significantly reduced increments were detected in Pr2x7
−/− animals, which showed
also decreased modulation of genes of lipid metabolism. Deletion of Pr2x7 gene was associated with blunted or abolished
activation of NLRP3 inflammasome and expression of its components, which were induced in liver sinusoidal endothelial cells
challenged with appropriate stimuli. These data show that Pr2x7 gene deletion protects mice from HFD-induced NASH,
possibly through blunted activation of NLRP3 inflammasome, suggesting that PR2X7 and NLRP3 may represent novel
therapeutic targets.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) has become the
leading cause of chronic liver disease worldwide [1], as a
result of the epidemics of obesity and type 2 diabetes. It
encompasses a wide spectrum of disease conditions, from
simple steatosis to nonalcoholic steatohepatitis (NASH), cir-
rhosis, and hepatocellular carcinoma [2]. Transition from
steatosis to NASH is characterized by superimposition of
inflammation and hepatocyte degeneration and death, ulti-
mately leading to tissue fibrosis [3]. Lipotoxicity from nontri-
glyceride fatty acid metabolites is now recognized as a central
mechanism driving hepatic inflammation and injury. When
flux of free fatty acids (FFAs) from diet, adipose tissue
lipolysis, and hepatic de novo lipogenesis is higher than the
rate of FFA oxidation or incorporation into triglycerides for
storage as lipid droplets or export as VLDL, exceeding FFAs
can generate lipotoxic intermediates which may induce oxi-
dative stress, endoplasmic reticulum stress, mitochondrial
dysfunction, and overproduction of proinflammatory cyto-
kines and adipokines [4, 5]. However, the precise molecular
mechanism triggering steatosis progression to NASH has
not been elucidated yet.
A growing body of evidence indicates a major role for
the purinergic system, particularly extracellular ATP (eATP)
signaling through the purinergic receptor 2X7 (PR2X7), in
several inflammatory and fibrotic disorders including NASH
[6, 7]. In detail, Das et al. showed that Pr2x7 gene deletion
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was associated with protection from liver injury in two rodent
models of NASH: the toxin-induced model, using coadminis-
tration of a high-fat diet (HFD) and a low-dose environmental
toxin bromodichloromethane, and the diet-induced model,
using a methionine choline-deficient (MCD) diet [8]. Like-
wise, Hoque et al. reported that mice knockout for Pr2x7
gene (Pr2x7
−/−) as well as wild-type (WT) mice treated
with the specific PR2X7 antagonist A438079 exhibited
significantly decreased acetaminophen hepatotoxicity [9].
Antagonism of PR2X7 with A438079 and Brilliant blue G
was also found to attenuate liver fibrosis induced by carbon
tetrachloride in mice [10] and common bile duct ligation in
rats [11], respectively.
Stimulation of PR2X7 by eATP results in rapid opening of
a ligand-gated cation channel, followed by induction of a
cytoplasmic pore via pannexin-1, which triggers K+ efflux
and allows danger signals to access the cytosol and acti-
vate the nucleotide-binding and oligomerization domain
(NOD), leucine-rich repeat, and pyrin domain containing
(NLRP) 3 inflammasome [12]. The NLRP3 inflammasome
is expressed primarily in macrophages and dendritic cells
[13], but also in nonhematopoietic tissues, including the liver
at the level of hepatocytes, Kupffer cells, endothelial cells,
stellate cells, and myofibroblasts [14]. This multiprotein
platform is composed of an inflammasome sensor molecule,
containing an N-terminal pyrin domain (PYD) and a caspase
recruitment domain (CARD). Once activated, it oligomerizes
and recruits the PYD-CARD adaptor protein apoptosis-
associated speck-like protein containing a CARD (PYCARD
or ASC) and the protease procaspase-1. Caspase-1 auto-
activation results in the cleavage of prointerleukin- (IL-) 1β
and IL-18 into their mature form, which are released [13].
In addition to mediating inflammation via canonical IL-1β
and IL-18-dependent mechanisms, the NLRP3 inflamma-
some regulates cell death through noncanonical caspase-1-
dependent and independent pathways leading to pyroptosis
and pyronecrosis, respectively [15].
We have previously shown that deletion of Pr2x7 gene
attenuated renal disease in mice fed a HFD and that this
was associated with blunted upregulation of the NLRP3
inflammasome components NLRP3, ASC, procaspase-1,
pro-IL-1β, and pro-IL-18 and reduced the formation of
mature caspase-1 [16]. The observation that PR2X7 was
required for eATP-stimulated IL-1β release in Kupffer cells
supports the hypothesis that also in the liver the effects of
PR2X7 stimulation are mainly mediated by NLRP3 activation
[9]. Indeed, numerous experimental observations suggest an
involvement of NLRP3 in transition from steatosis to NASH
[14]. Treatment with the NLRP3 inflammasome blocker
MCC950 attenuated liver inflammation and fibrosis in two
mouse models of NASH, that is, the Alms1 mutant (foz/foz)
mice fed with an atherogenic diet and C57BL/6 mice fed with
an MCD diet [17]. Likewise, deletion of the NLRP3 gene
protected from NASH induced by choline-deficient amino
acid-defined diet [18], though another report found exacer-
bated MCD diet-induced hepatic steatosis and inflammation
mediated by gut microbial dysbiosis [19]. Conversely, Nlrp3
knockin mice showed accelerated NASH [18, 20], associated
with marked hepatocyte pyroptosis [20].
This study aimed at investigating the effect of Pr2x7 gene
deletion on the development of experimental NASH induced
by HFD in mice.
2. Methods
2.1. Design. The study design consisted of (a) in vivo studies,
in which we assessed whether disruption of the Pr2x7 gene
attenuates NASH via blunted activation of the NLRP3
inflammasome, and (b) in vitro studies, in which we assessed
whether PR2X7-dependent activation of the NLRP3 inflam-
masome occurs also at the level of resident liver cells. In the
in vivo studies, adult (aged six weeks), male Pr2x7
−/−and coe-
val WT mice were used. The Pr2x7
−/− mice were of the two
currently available strains, that is, the Pfizer strain, back-
crossed onto a B6D2 background, which has a neomycin
cassette (Neo) inserted into exon 13 [21], and the GlaxoS-
mithKline strain, backcrossed onto a C57BL6 background,
which has a LacZ gene and Neo inserted into exon 1 [22].
The Pr2x7
−/− mice of Pfizer strain were purchased from
Jackson Laboratory (Bar Harbor, ME), whereas those of the
GlaxoSmithKline strain were kindly provided by Professor
Francesco Di Virgilio (University of Ferrara, Ferrara, Italy).
The reason for using the two strains is that splice variants
with reduced function may escape inactivation in selected
tissues from both the Pfizer [23] and the GlaxoSmithKline
[24] strain. Mice were housed in a germ-free stabularium in
accordance with the Principles of Laboratory Animal Care
(NIH Publication number 85–23, revised 1985) and with
national laws and received water and food ad libitum. The
study protocol was approved by the locally appointed ethics
committee. Mice from both genotypes were fed for 16 weeks
either a HFD (DIO diet D12492, 60% of total calories from
fat) or a normal-fat diet (NFD, DIO diet D12450B; 10% of
total calories from fat), purchased from Research Diets
(Mucedola, Settimo Milanese, Italy). The four groups con-
sisted of 12–14 animals each, half of the Pfizer strain and half
of the GlaxoSmithKline strain. At the end of the 16-week
period, mice were anaesthetized with intraperitoneal keta-
mine (Imalgene®, 60mg/kg body weight) and xylazine
(Rompum®, 7.5mg/kg body weight) and a longitudinal
incision of the abdominal wall was performed, a blood
sample was obtained, and the liver was removed and
weighed. Then, a portion of liver tissue was immediately
fixed by immersion in phosphate buffered 4% formaldehyde
solution and processed for light microscopy examination,
morphometrical evaluation, and immunohistochemistry.
The remaining liver tissue was frozen in liquid nitrogen
and used for extraction of proteins and total RNA [25]. In
the in vitro studies, human liver sinusoidal endothelial cells
(LSECs) were plated onto fibronectin-coated dishes and
cultured in endothelial cell medium supplemented with 5%
FBS, antibiotics, and endothelial cell growth supplement
(ScienCell Research Laboratories, Carlsbad, CA), at 37°C in
95% air-5% CO2 humidified atmosphere. Cells were then
incubated for 21 hours with serum-free medium containing
100 ng/ml recombinant human tumor necrosis factor-
(TNF-) α (PeproTech, Rocky Hill, NJ) followed by 0.2mM
2′(3′)-O-(4-benzoylbenzoyl)ATP (BzATP, Sigma-Aldrich,
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Table 1: Metabolic parameters and liver enzymes. Body weights and levels of glucose, insulin, HOMA-IR index, cholesterol, triglycerides,
FFAs, AST, and ALT in WT and Pr2x7
−/− mice fed with a NFD or a HFD (mean± SD; n = 7 per group).
WT-NFD Pr2x7
−/−-NFD WT-HFD Pr2x7
−/−-HFD
Body weight, g 31.8± 2.3 32.6± 1.9 41.2± 5.5∗ 40.6± 1.5∗
Glucose, mmol·l−1 5.56± 0.88 5.63± 0.73 9.01± 0.71∗ 8.85± 1.08∗
Insulin, pmol·l−1 63.9± 18.7 58.3± 11.5 158.1± 18.1∗ 151.9± 19.1∗
HOMA-IR 2.21± 0.79 2.05± 0.56 8.84± 1.32∗ 8.38± 1.86∗
Cholesterol, mmol·l−1 2.64± 0.31 2.62± 0.54 3.93± 0.62∗ 3.82± 0.31∗
Triglycerides, mmol·l−1 0.56± 0.21 0.57± 0.17 1.78± 0.52∗ 1.42± 0.29∗
FFA, mEq·l−1 0.33± 0.05 0.31± 0.06 0.95± 0.11∗ 0.83± 0.09∗
AST, UI·l−1 33.6± 5.6 31.3± 4.6 87.1± 12.3∗ 55.9± 7.1∗†
ALT, UI·l−1 22.6± 7.2 18.6± 3.6 111.4± 18.4∗ 58.3± 15.7∗†
HOMA-IR = homeostasis model assessment-insulin resistance; FFAs = free fatty acids; AST = aspartate transaminase; ALT = alanine transaminase; WT =wild
type; Pr2x7
−/− = knockout for purinergic receptor X27 gene; NFD = normal-fat diet; HFD= high-fat diet.
∗P < 0 001 versus the corresponding NFD-fed mice;
†P < 0 001 versus WT mice.
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Figure 1: NAFLD grading and staging. Hematoxylin and eosin staining of liver sections from representative animals ((a); original
magnification 100x) and NAFLD (steatosis) grading (b) and staging (c) in NFD- and HFD-fed WT and Pr2x7
−/− mice (n = 7 per group).
P = portal area; CV= centrolobular vein. The box indicates mice fulfilling NASH criteria. ∗P < 0 05 versus WT mice. NAFLD=nonalcoholic
fatty liver disease; NFD=normal-fat diet; HFD=high-fat diet; WT=wild type; Pr2x7
−/−= knockout for purinergic receptor 2X7 gene;
NASH=nonalcoholic steatohepatitis.
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Saint Louis, MO) for 45min. Cell lysates were then col-
lected [16]. This stimulus was chosen in order to mimic
the sterile inflammation occurring in NASH, consistent
with a very recent report showing a key role for TNF-α as
a mediator of liver inflammation and fibrosis induced by
constitutive NLRP3 inflammasome activation in myeloid-
derived cells [26].
2.2. Liver Morphology/Morphometry. Liver morphology was
assessed based on the American Association for the Study of
Liver Disease Guidelines [27], as previously reported [25].
Briefly, NAFLD was graded and staged in hematoxylin and
eosin-stained sections. NAFLD grading was assessed based
on the percentage of parenchyma involved by steatosis
(grades 0 to 3 as follows: 0, no fat; 1, <33%; 2, 33–66%;
and 3, >66%). The steatosis grade and the presence of
inflammation, hepatocyte degeneration (acidophil or Coun-
cilman’s bodies, ballooning, and Mallory’s hyaline) or
necrosis, and fibrosis were then considered for NAFLD stag-
ing (stages 1 to 4, with stages 3 and 4 corresponding to
NASH). Subsequently, samples from mice with NAFLD
stage 3 and 4 were graded and staged for NASH. NASH
grading was accomplished based on the type of fat (macro-
vesicular, microvesicular, or mixed) and the extent of
inflammation (scored 0 to 3 as follows: 0, no; 1, mild; 2,
moderate; and 3, severe) and hepatocyte degeneration or
necrosis. NASH staging was performed by assessing the
extent and distribution of fibrosis in sections stained with
Masson’s trichrome.
2.3. Biochemistry and ELISA. Blood samples obtained from
experimental animals were analyzed for fasting levels of glu-
cose, with the aid of an automated colorimetric instrument
(Glucocard™ SM, A. Menarini Diagnostics, Florence, Italy);
cholesterol, triglycerides, aspartate transaminase (AST), and
alanine transaminase (ALT), by standard chemical methods
(VITROS5.1 FS Chemistry System, Ortho-Clinical Diagnos-
tics, Rochester, NY); free fatty acids (FFAs), using the NEFA
C kit (Wako, Osaka, Japan); and insulin, by enzyme immu-
noassay (Ultrasensitive Mouse Insulin ELISA kit, Mercodia
AB, Uppsala, Sweden). The homeostasis model assessment-
insulin resistance (HOMA-IR) index was then calculated
from fasting glucose and insulin [16, 25]. Hepatic levels of
eATP were assessed colorimetrically in liver tissue homoge-
nates using the ATP assay kit (ab83355, Abcam, Cambridge,
UK) as per manufacturer’s instructions.
2.4. Immunohistochemistry and Western Blot Analysis. Liver
content and distribution of the advanced glycation end prod-
uct (AGE) Nε-(carboxymethyl)lysine (CML) and the 47 kDa
cytosolic subunit of neutrophil NADPH neutrophil cytosol
factor 1 (NCF1, also known as p47phox) were assessed by
immunohistochemistry, together with protein expression of
PR2X7 and NLRP3. The primary and secondary antibodies
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Figure 2: NASH grading and staging. Hematoxylin and eosin ((a); original magnification 250x) and Masson’s trichrome ((c); original
magnification 250x) staining of liver sections from representative animals; and NASH grading (c) and staging (d) in the HFD-fed
WT (n = 4) and Pr2x7−/− (n = 1) mice fulfilling NASH criteria. P = portal space; CV= centrolobular vein; B = ballooning degeneration;
M=Mallory’s body; INF = inflammation. NASH=nonalcoholic steatohepatitis; HFD=high-fat diet; WT=wild type; Pr2x7
−/−= knockout
for purinergic receptor 2X7 gene.
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used are reported in Supplemental Table 1 available online at
https://doi.org/10.1155/2017/8962458. Staining was analyzed
using an image analysis system (Optimas™6.5, Bioscan,
Washington DC) at a fixed color threshold in 20 random
fields of the liver at a final magnification of 400x, and results
were expressed as the mean percentage of field area occupied
by the specific stain [16, 25]. Levels of caspase-1 in the liver
and LSECs were evaluated by Western blot analysis and nor-
malized to the levels of β-actin. The antibodies used are
reported in Supplemental Table 1. Bands were detected by
an enzymatic chemiluminescence kit (Immobilon Western,
Millipore, Billerica, MA) and quantified by scanning densi-
tometry using a GS-670 Imaging Densitometer (Bio-Rad
Laboratories, Hercules, CA) [16].
2.5. Quantitative Real-Time PCR. Total RNA was extracted
from the liver with the RNAeasy mini kit (Qiagen, Milan,
Italy). Then, 1 μg of RNA was reverse-transcribed in a 20 μl
reaction tube using high capacity cDNA reverse transcription
kit (Applied Biosystems,Monza, Italy). Quantitative real-time
PCR (qRT-PCR) was performed in triplicate using a
StepOne™ Real-Time PCR instrument (Thermo Fisher
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Figure 3: Oxidative and carbonyl stress markers. Immunohistochemistry for CML ((a); original magnification 100x) and NCF1 ((c); original
magnification 100x) in liver sections from representative animals and quantification of liver CML (b) and NCF1 (d) protein content in HFD-
fed WT and P2x7r
−/− mice (mean± SD; n = 4–6 per group). ∗P < 0 001 or †P < 0 05 versus the corresponding NFD-fed mice; ‡P < 0 001
versus WT mice. CML=Nε-(carboxymethyl)lysine; NCF1 = neutrophil cytosol factor 1; NFD=normal-fat diet; HFD=high-fat diet;
WT=wild type; Pr2x7
−/−= knockout for purinergic receptor 2X7 gene.
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Scientific, Monza, Italy) following the standard protocol.
The following transcripts were quantified by TaqMan gene
expression assays (Applied Biosystems) using the assays
reported in Supplemental Table 2: (a) the inflammatorymedi-
ators monocyte chemoattractant protein-1 (MCP-1, Ccl2),
TNF-α (Tnfa), and interferon-γ (Ifng); (b) the markers of
activated Th1 lymphocytes and murine macrophage activa-
tion, CX chemokine receptor 3 (Cxcr3) and F4/80 (Adgre1),
respectively; (c) the regulator of ER stress-mediated apoptosis
CCAAT/enhancer-binding protein (C/EBP) homologous
protein (CHOP, Ddit3); (d) the receptor for AGEs (RAGE,
Ager); (e) the extracellular matrix proteins fibronectin
(Fn1) and collagen I (Col1a1) and the profibrotic cytokine
transforming growth factor-β1 (Tgfβ1); (f) the transcrip-
tion factors regulating lipid metabolism, sterol regulatory
element-binding transcription factor 1c (Srebf1), peroxi-
some proliferator-activated receptor α and γ (Ppara and
Pparg), and liver X receptor (LRX) α and β (Nr1h3 and
Nr1h2); (g) the enzymes of fatty acid synthesis, acetyl-
CoA carboxylase (Acaca) and FA synthase (Fasn), of fatty
acid β-oxidation, carnitine palmitoyltransferase I (Cpt1a)
and acyl-CoA oxidase 1 (Acox1), and of cholesterol syn-
thesis, hydroxymethylglutaryl-CoA reductase (Hmgcr); (h)
the protein responsible for triglyceride transfer to apolipo-
protein B100, microsomal triglyceride transfer protein
(Mttp); and (i) the components of the PR2X7-NLRP3 axis,
Pr2x7, Nlrp3, Pycard, procaspase-1 (Casp1), and Il1β. The
amount of the target gene was normalized to β-actin
(ACTB). Results were analyzed using the SDS 2.1 Applied
Biosystems software [28].
2.6. Statistical Analysis. Results are expressed as means± SD
or median and interquartile range and percent change versus
controls. Statistical significancewas evaluated by (a) Pearson’s
χ2 test for categorical variables; (b) Student’s t-test or one-way
ANOVA followed by the Bonferroni correction for multiple
comparisons for parametric continuous variables; and (c)
theMann–WhitneyU test or the Kruskal-Wallis test followed
by theWilcoxon’s signed ranks test for nonparametric contin-
uous variables. A p value< 0.05was considered significant. All
statistical tests were performed on raw data using the SPSS
version 13.0 (SPSS Inc., Chicago, IL).
3. Results
3.1. Metabolic Parameters and Liver Enzymes. Body weights
were significantly higher in mice on a HFD, as compared
with animals fed with a NFD. Likewise, blood glucose and
insulin concentrations, the HOMA-IR index, and triglycer-
ide, cholesterol, and FFA levels were higher in HFD- versus
NFD-fed mice. Interestingly, there was no difference between
the two genotypes of the Pfizer strain (Table 1), whereas
Pr2x7
−/−-HFD mice of the GlaxoSmithKline strain showed
no increase in body weight versus Pr2x7
−/−-mice and signifi-
cantly lower increments in glucose, insulin, HOMA-IR,
triglycerides, cholesterol, and FFAs than the corresponding
WT-HFD animals. To rule out the possibility that blunted
metabolic abnormalities per se may have resulted in
attenuated hepatic injury in the Pr2x7
−/− mice of the
GlaxoSmithKline strain, only data from the Pfizer strain are
presented herein, despite the fact that, at variance with met-
abolic parameters, all measures of liver function and struc-
ture were virtually identical between the two strains. Levels
of AST and ALT increased significantly in HFD-fed mice
from both genotypes, as compared with the corresponding
Table 2: Liver inflammation, fibrosis, and lipid metabolism. Liver
expression of genes of inflammation, fibrosis, and lipid metabolism
in WT and Pr2x7
−/− mice fed with a NFD or a HFD (mean± SD;
n = 4–7 per group). ∗P < 0 01 versus the corresponding NFD
mice; †P < 0 05 versus the corresponding WT mice.
WT-NFD Pr2x7
−/−-NFD WT-HFD Pr2x7
−/−-HFD
Inflammation
Ccl2 0.90± 0.30 0.98± 0.28 2.79± 0.79∗ 1.56± 0.49‡
Tnfa 1.07± 0.22 1.03± 0.58 2.18± 0.71† 1.13± 0.31§
Ifng 1.02± 0.13 1.03± 0.06 1.27± 0.20 1.18± 0.11
Cxcr3 0.97± 0.13 1.06± 0.26 2.86± 1.07∗ 1.65± 0.50#
Adgre1 1.08± 0.26 1.11± 0.55 2.54± 0.60∗ 1.62± 0.37§
Ddit3 1.01± 0.07 0.98± 0.08 1.93± 0.20∗ 1.17± 0.30‡
Ager 1.02± 0.07 1.03± 0.07 1.93± 0.18∗ 1.28± 0.38§
Fibrosis
Fn1 0.98± 0.06 0.92± 0.07 1.68± 0.29∗ 1.09± 0.03‡
Cola1a1 1.00± 0.17 0.93± 0.06 2.33± 0.49∗ 1.34± 0.27§
Tgfβ 1.08± 0.13 1.01± 0.22 1.84± 0.26∗ 1.50± 0.26†#
Lipid metabolism
Srebf1 0.91± 0.15 0.99± 0.22 3.80± 0.52∗ 1.90± 0.27∗‡
Ppara 0.97± 0.21 0.93± 0.07 1.90± 0.52† 1.45± 0.33
Pparg 0.92± 0.16 0.93± 0.15 2.52± 0.71∗ 1.47± 0.13§
Nr1h3 0.96± 0.09 0.92± 0.12 1.47± 0.14∗ 1.24± 0.10†#
Nr1h2 1.09± 0.12 1.12± 0.14 1.22± 0.21 1.23± 0.19
Acaca 0.87± 0.15 0.92± 0.11 1.21± 0.06∗ 0.97± 0.08‡
Fasn 0.96± 0.15 0.99± 0.20 1.53± 0.11∗ 1.19± 0.17§
Cpt1 0.95± 0.09 1.02± 0.19 2.45± 0.39∗ 1.64± 0.28∗‡
Acox1 0.95± 0.08 0.90± 0.14 1.07± 0.26 1.00± 0.22
Hmgcr 0.99± 0.05 0.98± 0.07 1.10± 0.16 1.05± 0.16
Mttp 0.91± 0.10 0.98± 0.08 0.91±±0.18 0.99± 0.23
WT =wild type; Pr2x7
−/− = knockout for purinergic receptor X27 gene;
NFD = normal-fat diet; HFD= high-fat diet; Ccl2 =monocyte
chemoattractant protein-1 (MCP-1) gene; Tnfa = tumor necrosis factor-α
gene; Ifng = interferon-γ gene; Cxcr3 = CX chemokine receptor 3 gene;
Adgre1 = F4/80 gene; Ddit3 =m CCAAT/enhancer-binding protein (C/EBP)
homologous protein (CHOP) gene; Ager = receptor for AGEs (RAGE) gene;
Fn1 fibronectin gene; Col1a1 = collagen I gene; tgfb1 = transforming growth
factor- (TGF-) β1 gene; Srebf1 = sterol regulatory element-binding
transcription factor 1c gene; Ppara = peroxisome proliferator-activated
receptor (PPAR) α gene; Pparg = peroxisome proliferator-activated receptor
(PPAR) γ gene; Nr1h3 = liver X receptor- (LRX-) α gene; Nr1h2 = LXR-β
gene; Acaca = acetyl-CoA carboxylase gene; Fasn = fatty acid synthase gene;
Cpt1a = carnitine palmitoyltransferase- (CPT-) I gene; Acox1 = acyl-CoA
oxidase 1 gene; Hmgcr = hydroxymethylglutaryl-CoA reductase gene;
Mttp =microsomal triglyceride transfer protein gene. ∗P < 0 001 or
†P < 0 01 versus the corresponding NFD-fed mice; ‡P < 0 001, §P < 0 01, or
#P < 0 05, versus WT mice.
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NFD-fed animals, though increases were significantly less
marked in Pr2x7
−/− than in WT animals (Table 1).
3.2. Grading and Staging of NAFLD and NASH. Steatosis was
detected only in HFD-fed mice from both genotypes, though
it was of higher grade in WT than in Pr2x7
−/− mice
(Figure 1(a)). In detail, NAFLD grading showed that three
out of 7 WT-HFD mice fell in grade 3 steatosis, whereas four
out of 7 Pr2x7
−/−-HFD mice were assigned to grade 1 steato-
sis (Figure 1(b)). Likewise, NAFLD grading showed that, of
the WT-HFD mice, three had stage 2 (predominantly micro-
vesicular steatosis with mild lobular inflammation), three
had stage 3 (mixed steatosis with lobular inflammation and
ballooningdegeneration), andonehad stage4 (mixed steatosis
with lobular inflammation and ballooning degeneration and
macrovesicular steatosis, associated with portal and lobular
inflammation,Councilman’sbodies, ballooningdegeneration,
Mallory’s hyaline, and fibrosis) NAFLD. Conversely, only
one of the Pr2x7
−/−-HFD animals fell in stage 3 NAFLD,
whereas the remaining six mice did not fulfill NASH
criteria, as one had stage 2 and five had stage 1 (simple
steatosis) NAFLD (Figure 1(c)). Of the four WT-HFD
animals classified as having NASH, three showed grade 2
(moderate) and one grade 3 (severe or florid) NASH, whereas
one exhibited stage 2 (zone 3 portal/periportal, perivenular/
centrolobular, perisinusoidal/pericellular fibrosis; focal or
extensive) and three stage 1 (i.e., as stage 2, except portal
fibrosis) fibrosis (Figures 2(a) and 2(b)). The only one
Pr2x7
−/− mouse fulfilling NASH criteria was graded 1 (mild)
for NASH and staged 1 for fibrosis (Figures 2(c) and 2(d)).
3.3. Markers of Liver Inflammation, Fibrosis, and Lipid
Metabolism. The liver content of CML (Figures 3(a) and
3(b)) and NCF1 (Figures 3(c) and 3(d)) was markedly
increased in HFD-fed WT and, to a significantly lesser
extent, Pr2x7
−/− mice. Transcripts of the markers of inflam-
mation and endoplasmic reticulum and carbonyl stress Ccl2,
Tnfa, Cxcr3, Adgre1, Ddit3, and Ager, but not Ifng, increased
significantly in WT-HFD mice, but not in Pr2x7
−/−-HFD
animals (Table 2). Likewise, the mRNA expression levels of
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Figure 4: Hepatic PR2X7 expression. Immunohistochemistry for PR2X7 in liver sections from representative animals ((a); original
magnification 100x) and quantification of liver PR2X7 protein content (b), Pr2x7 mRNA expression (c), and eATP levels (d) in NFD- and
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the extracellular matrix components Fn1 and Col1a1
increased significantly in WT, but not Pr2x7
−/− mice on a
HFD, whereas those Tgfβ increased to a much lesser extent
in Pr2x7
−/− than in WT animals (Table 2). In response to
the HFD, marked changes were observed in the gene expres-
sion level of several transcription factors and enzyme of lipid
metabolism. In particular, transcript expression of Srebf1
and, to a lesser extent, of Ppara, Pparg, and Nr1h3 increased
in WT-HFD mice, but not or significantly less markedly in
Pr2x7
−/−-HFD animals. In response to the HFD, also tran-
scripts of Acaca, Fasn, and Cpt1 increased only or signifi-
cantly more in WT, as compared with Pr2x7
−/−mice. In
contrast, no significant effect of HFD or Pr2x7
−/− gene dele-
tion was observed in the mRNA levels of Nr1h2, Acox1,
Hmgcr, and Mttp (Table 2).
3.4. Liver Expression and Activation of the PR2X7/NLRP3
Axis. Staining for PR2X7 was observed at both the hepatocyte
and sinusoidal level in HFD-fed WT mice, whereas it was
only faint in those receiving a NFD (Figures 4(a) and 4(b)).
Likewise, liver mRNA expression of Pr2x7 was significantly
higher in HFD- versus NFD-fed WT animals, as assessed
by RT-PCR (Figure 4(c)). Levels of eATP increased signifi-
cantly in HFD-fed WT and to a lesser extent Pr2x7
−/− mice
(Figure 4(d)). Also, NLRP3 protein expression was markedly
increased in the liver of WT-HFD mice, as shown by the de
novo appearance of a strong positive staining for NLRP3 in
cells lining the hepatic sinusoids and bile ducts and in
infiltrating inflammatory cells, but not in hepatocytes.
Conversely, virtually no NLRP3 staining was observed in
PR2X7
−/−-HFD animals (Figures 5(a) and 5(d)). Consis-
tently, Nlrp3 mRNA levels were significantly increased in
the liver of WT, but not Pr2x7
−/− mice fed with a HFD
(Figure 5(e)). Similar changes were observed in the hepatic
gene expression of Pycard, Casp1, and Il1β, which were
increased in WT, but no or significantly less in Pr2x7
−/− on
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Figure 5: Hepatic NLRP3 expression. Immunohistochemistry for NLRP3 in liver sections from representative animals ((a) original
magnification 400x, additional staining pattern features in HFD-fed WT mice in (b) original magnification 400x, and (c) original
magnification 1000x oil immersion) and quantification of liver NLRP3 protein content (d) and Nlrp3 mRNA expression (e) in NFD- and
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a HFD (Figures 6(a), 6(b), and 6(c)). Finally, Western blot
analysis showed that the 20 kDa subunit (active caspase-1)
was significantly increased in response to the HFD in WT,
but not in Pr2x7
−/− mice (Figures 6(d) and 6(e)).
3.5. Cell Culture Experiments. Exposure of LSECs to TNF-
α+Bz-ATP resulted in a marked upregulation of the gene
expression levels of Ccl2, Pr2x7, Nlrp3, Casp1, and Il1β
(Figure 7(a)) and in the activation of caspase-1, as shown
by the appearance of a 20 kDa band at Western blot analysis
(Figure 7(b)).
4. Discussion
This study provides the experimental evidence that Pr2x7
gene deletion results in attenuation of NASH induced by a
HFD, a well-established model of the human metabolic
syndrome, as well as in blunted expression and activation
of the NLRP3 inflammasome, which may ultimately mediate
protection from liver injury.
The protective effect of Pr2x7 gene deletion toward
NASH is attested by the decreased inflammation, hepatocyte
degeneration, and fibrosis at histological examination and
the reduced or abolished increment in the protein and/or
gene expression of several proinflammatory, prooxidant,
and profibrotic markers. These results are consistent with a
previous report showing that Pr2x7 gene deletion attenuates
hepatic inflammation and fibrosis in different animal models
of NASH [8] and also with the findings that lack or blockade
of PR2X7 prevents other experimentally induced liver
diseases [9–11].
Interestingly, also hepatic fat accumulation was lower in
Pr2x7
−/− than in WTmice fed with a HFD, a finding attribut-
able to a favorable effect of Pr2x7 gene knockout on the
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Figure 6: Hepatic NLRP3 inflammasome expression and activation. Liver mRNA expression of Casp1 (a), Pycard (b), and Il1β (c); Western
blot analysis of caspase-1 and housekeeping β-actin in liver protein extracts from representative animals (d) and quantification of 20 kDa
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expression of transcription factors and enzymes of lipid
metabolism. In particular, the upregulation of those involved
in de novo lipogenesis, such as Srebf1, Ppara, Pparg, Nr1h3,
Acaca, and Fasn, was significantly blunted in Pr2x7
−/− mice,
as compared with WT animals. These data support the con-
cept that the protection afforded by Pr2x7 gene deletion was
related not only to reduction of the proinflammatory and
profibrotic response to the HFD but also to decreased
lipotoxicity driving hepatocyte injury and release of danger
signals such as eATP, which activate the innate immune
system. This interpretation is consistent with the lower levels
of eATP detected in the liver of Pr2x7
−/− versusWTmice on a
HFD and also with the finding that FFAs (and glucose) are
capable of upregulating Pr2x7 [29], thus implying that the
activation of purinergic signaling may occur at an early stage
in HFD-fed mice, prior to the occurrence of inflammation-
dependent hepatocyte degeneration and death.
The attenuation of NAFLD/NASH observed in PR2x7−/−
mice could not be attributed to a better metabolic profile. In
fact, a reduced liver injury was observed not only in animals
of the GlaxoSmithKline strain, which appeared to be partly
protected from metabolic dysfunction induced by the HFD
feeding, but also in those of the Pfizer strain, which did not
show any improvement in metabolic parameters. The differ-
ent metabolic responses observed in the two strains are in
keeping with previous studies reporting that expression of
splice variants which escape inactivation and maintain func-
tion, though to a reduced extent, may occur in selected tissue
of Pr2x7
−/−mice from both strains [23, 24]. In addition, the
finding that mice of the Pfizer strain developed the character-
istic features of the metabolic syndrome, including obesity,
dyslipidemia, hyperglycemia, and insulin resistance, to the
same extent as their correspondingWT animals, is consistent
with a previous report by Sun et al. In fact, these authors
showed no change in metabolic phenotype (and adipose
tissue inflammasome activation) in mice from this strain,
though they did not referred these unexpected results to
splice variants of Pr2x7 transcripts [30].
The association of Pr2x7 gene deletion with blunted
hepatic activation of the NLRP3 inflammasome points to a
major role of purinergic signaling through PR2X7 in trigger-
ing of this process in the liver of HFD-fed mice. All the three
not mutually exclusive models proposed for inflammasome
activation might have been responsible for the activation of
NLRP3 inflammasome in these animals [31]. In fact, dead
hepatocytes may have released eATP [9] and uric acid [32],
thus inducing pore formation via PR2X7 and frustrated
phagocytosis with consequent lysosomal disintegration and
release of proteases, respectively [31]. In addition, multiple
signals may have caused generation of reactive oxygen spe-
cies (ROS) via NADPH oxidase or mitochondrial sources,
which is thought to represent a common final pathway lead-
ing to inflammasome activation [31]. These signals include
glucose [33], saturated FFAs such as palmitate [34], the
lipotoxic FFA metabolite ceramide [35], and modified lipo-
proteins such as oxidized LDLs, which may also act via
formation of cholesterol crystals [36]. In addition, Chatterjee
et al. recently showed that, in Kupffer cells, PR2X7 mediates
NADPH oxidase activation by upregulating the expression
of the p47 phox subunit and p47 phox binding to the mem-
brane subunit, gp91 phox [37], consistent with our finding
of a reduced liver expression of NCF1 (p47 phox) in
Pr2x7
−/− animals. Other possible mechanisms implicated in
the PR2X7-mediated activation of the NLRP3 inflammasone
include the induction of endoplasmic reticulum stress [38]
and the impairment of autophagy [39], which have been
implicated in the development of NASH [8, 40]. Finally, the
release of microvesicles from fat-laden hepatocytes may
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promote activation of NLRP3 in surrounding hepatocytes via
a paracrine mechanism [41].
As previously shown at the kidney level, also the
expression of NLRP3 inflammasome components was
blunted in liver tissue of HFD-fed Pr2x7
−/− mice, thus
suggesting that stimulation of PR2X7 is involved also in
priming the inflammasome through activation of nuclear
factor-κB (NF-κB) via multiple mechanisms. Activation
of NADPH oxidase by PR2X7-mediated increase of
TNF-α levels through autophagy-linked inflammation may
play a major role in this respect [8, 37]. Moreover, the
decreased levels of CML and Ager and the improved lipid
metabolism detected in the liver of these mice suggest
that PR2X7 also modulates the activation of NF-κB
induced by carbonyl stress [42] and FFAs [43] via oxidant-
dependent mechanisms. Activation of procaspase-1 and
release of mature IL-1β induced by PR2X7-mediated
inflammasome activation might also be important in
sustaining NF-κB activation via induction of TNF-α
[44]. Figure 8 summarizes the potential mechanisms
involved in PR2X7-mediated expression/activation of the
NLRP3 inflammasome.
The finding that both the expression and the activation of
the NLRP3 inflammasome were blunted in Pr2x7
−/− mice
supports the hypothesis that this effect of Pr2x7 gene deletion
was a major mechanism mediating protection from NASH.
This interpretation is consistent with previous observations
showing that Nlrp3 gene deletion [18] or NLRP3 blockade
[17] attenuates hepatic inflammation and fibrosis in animal
models of NASH, and also with the evidence that these strat-
egies are effective in attenuating other experimentally
induced liver diseases [14].
A debated issue is the contribution of resident cells to
inflammasome activation and inflammasome-mediated tis-
sue injury in inflammatory and fibrotic disorders. Indeed,
in the liver of WT-HFD mice, the NLRP3 inflammasome
was expressed in both resident and nonresident cells. In
addition, inflammasome activation was induced in LSECs
challenged with TNF-α+BzATP, that is, a primer and an
activator of this multiprotein platform. These data are consis-
tent with the concept that also resident cells are involved, as
previously shown in the kidneys of these animals [16]. Csak
et al. found that both bone marrow- (BM-) derived and
non-BM-derived cells contributed to NLRP3 inflammasome
activation in a myeloid differentiation primary response gene
88- (MyD88-) dependent manner in NASH induced by
MCD diet, though only BM-derived cell-specific MyD88-
deficiency attenuated liver injury [45]. Conversely, Wree
et al. reported that acceleration of NASH was lower in
BM-specific than in global Nl3p3 knockin mice, thus
pointing to an important contribution of resident cells to
liver injury [20].
A limitation of this study is the use of LSECs only
to assess whether PR2X7-dependent activation of the
NLRP3 inflammasome occurs also at the level of resident
liver cells. However, our aim was to test this hypothesis
in a nonimmune cell type of the liver other than hepa-
tocytes, which did not show any NLRP3 protein expression
at IHC.
5. Conclusion
These data demonstrate a major contribution of PR2X7,
possibly via activation of the NLRP3 inflammasome, in
hepatic inflammation and injury driving transition from
steatosis to NASH in the context of NAFLD. This study
identifies P2X7R and NLRP3 as novel therapeutic targets
for liver disease associated with metabolic disorders.
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